A COMPARATIVE ASSESSMENT OF SERUM CREATININE AND CYSTATIN C AS A SIGNIFICANCE OF NEPHROPATHY IN DIABETIC PATIENTS

  • Maytham Salim Al-Nasrawii Community Health Department, Technical Institute of Karbala, AL-Furat Al-Awsat Technical University, Iraq https://orcid.org/0000-0001-8807-9785
  • Balqees Sadoon Jasim Community Health Department, Technical Institute of Karbala, AL-Furat Al-Awsat Technical University, Iraq https://orcid.org/0000-0002-1837-1956
  • Salim Hussein Hassan Community Health Department, Technical Institute of Karbala, AL-Furat Al-Awsat Technical University, Iraq
Keywords: Diabetic Nephropathy, Cystatin C, Serum Creatinine, Type 2 DM

Abstract

The critical micro-vascular complications of diabetes ultimately result in renal dysfunction known as diabetic nephropathy (DN). Measurement of glomerular filtration rate (GFR) is considered to be an important parameter in renal function assessment, evaluating GFR by Creatinine level. Recently, Cystatin C is used as a substitute indicator in several studies to assess diabetic nephropathy. This work was conceived to determine whether serum cystatinC would replace serum creatinine (Scr) in patients with type2 diabetes for early evaluation of nephropathy. A Case-Control Study was enrolled on 30 Patients with diabetic and 30 apparently healthy as control, aged between 25 - 83 years. Levels of serum cystatine C and serum Creatinine were calculated for both groups. Serum Creatinine, as well as serum cystatin C levels, was significant relationship with diabetic pt. in compared to non-diabetic individuals. ROC analysis noted the cystatinC was more predict indicator in diagnosed Diabetic Nephropathy (DNP) from Serum Creatinine level. In Type 2 diabetics, CystatinC is a good marker for uncontrolled diabetic nephropathy relative to serum creatinine.

References

Afkarian, M. (2015). Diabetic kidney disease in children and adolescents. Pediatric nephrology, 30(1), 65-74.

Zychowska, M., Rojewska, E., Przewlocka, B., & Mika, J. (2013). Mechanisms and pharmacology of diabetic neuropathy–experimental and clinical studies. Pharmacological Reports, 65(6), 1601-1610.

Mise, K., Hoshino, J., Ueno, T., Sumida, K., Hiramatsu, R., Hasegawa, E., ... & Fujii, T. (2014). Clinical implications of linear immunofluorescent staining for immunoglobulin G in patients with diabetic nephropathy. Diabetes research and clinical practice, 106(3), 522-530.

MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014). Markers of and risk factors for the development and progression of diabetic kidney disease. American journal of kidney diseases, 63(2), S39-S62.

Josipović, J., Katičić, D., & Pavlović, D. (2013). Dijabetička nefropatija: dijagnostika, prevencija, liječenje. Medix, 19(107/108), 200-206.

Al-Wakeel, J. S., Hammad, D., Al Suwaida, A., Mitwalli, A. H., Memon, N. A., & Sulimani, F. (2009). Microvascular and macrovascular complications in diabetic nephropathy patients referred to nephrology clinic. Saudi Journal of Kidney Diseases and Transplantation, 20(1), 77-86.

Stumvoll, M., Goldstein, B. J., & Van Haeften, T. W. (2005). Type 2 diabetes: principles of pathogenesis and therapy. The Lancet, 365(9467), 1333-1346.

Steffes, M. W. (2006). Estimating GFR from cystatin C in serum: Seeking to enhance its clinical application. American journal of kidney diseases, 48(5), 842-843.

Chung, J. O., Cho, D. H., Chung, D. J., & Chung, M. Y. (2015). Serum cystatin C levels are positively associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes, 123(10), 627-631.

Biesenbach, G., & Pohanka, E. (2012). Dialysis in diabetic patients: hemodialysis and peritoneal dialysis. Pros and cons. Minerva urologica e nefrologica= The Italian journal of urology and nephrology, 64(3), 173-182.

Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., ... & Coresh, J. (2012). Estimating glomerular filtration rate from serum creatinine and cystatin C. New England Journal of Medicine, 367(1), 20-29.

Anderson, A. H., Yang, W., Hsu, C. Y., Joffe, M. M., Leonard, M. B., Xie, D., ... & Kusek, J. W. (2012). Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) study. American journal of kidney diseases, 60(2), 250-261.

Shlipak, M. G., Matsushita, K., Ärnlöv, J., Inker, L. A., Katz, R., Polkinghorne, K. R., ... & Levey, A. S. (2013). Cystatin C versus creatinine in determining risk based on kidney function. New England Journal of Medicine, 369(10), 932-943.

Salgado, J. V., Souza, F. L., & Salgado, B. J. (2013). How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence?. Journal of cardiology, 62(6), 331-335.

Rule, A. D., Larson, T. S., Bergstralh, E. J., Slezak, J. M., Jacobsen, S. J., & Cosio, F. G. (2004). Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Annals of internal medicine, 141(12), 929-937.

Herget-Rosenthal, S., Bökenkamp, A., & Hofmann, W. (2007). How to estimate GFR-serum creatinine, serum cystatin C or equations?. Clinical biochemistry, 40(3-4), 153-161.

Zürbig, P., Jerums, G., Hovind, P., MacIsaac, R. J., Mischak, H., Nielsen, S. E., ... & Rossing, P. (2012). Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes, 61(12), 3304-3313.

Al-Tu’ma, F. J., Dheyauldeen, M. H., & Al-Saegh, R. M. (2017). Measurement of urinary kidney injury molecule-1 as a predictive biomarker of contrast-induced acute kidney injury. Journal of Contemporary Medical Sciences, 3(9), 178-181.

Qiu, X., Liu, C., Ye, Y., Li, H., Chen, Y., Fu, Y., ... & Liu, H. (2017). The diagnostic value of serum creatinine and cystatin c in evaluating glomerular filtration rate in patients with chronic kidney disease: a systematic literature review and meta-analysis. Oncotarget, 8(42), 72985.

Bargnoux, A. S., Kuster, N., Cavalier, E., Piéroni, L., Souweine, J. S., Delanaye, P., & Cristol, J. P. (2018). Serum creatinine: advantages and pitfalls. Journal of Laboratory and Precision Medicine.

Slort, P. R., Ozden, N., Pape, L., Offner, G., Tromp, W. F., Wilhelm, A. J., & Bokenkamp, A. (2012). Comparing cystatin C and creatinine in the diagnosis of pediatric acute renal allograft dysfunction. Pediatric Nephrology, 27(5), 843-849.

MacIsaac, R. J., Premaratne, E., & Jerums, G. (2011). Estimating glomerular filtration rate in diabetes using serum cystatin C. The Clinical Biochemist Reviews, 32(2), 61-65..

Hojs, R., Bevc, S., Ekart, R., Gorenjak, M., & Puklavec, L. (2006). Ocena glomerulne filtracije–primerjava serumskega kreatinina, serumskega cistatina c in enačb za izračun očistka kreatinina. TEST-ZV, 75-80.

Gupta, K., Nayyar, S. B., Sachdeva, J., & Kumar, P. (2017). Cystatin C in the early diagnosis of diabetic nephropathy and its correlation with albuminuria. International Journal of Advances in Medicine, 4(1), 56-59.

Shetty, V., Jain, H. R., Singh, G., Parekh, S., & Shetty, S. (2017). Plasma Cystatin C as Marker of Early Renal Impairment in Diabetes Mellitus. International Journal of Scientific Study, 4(12), 1-7.

Waheed, H. J. (2015). A comparative study for cystatin c and some biochemical markers for predicting diabetic nephropathy in Iraqi patients. Int J Curr Microbiol App Sci, 4, 108-114.

Sagheb, M. M., Namazi, S., Geramizadeh, B., Karimzadeh, A., Oghazian, M. B., & Karimzadeh, I. (2014). Serum cystatin C as a marker of renal function in critically ill patients with normal serum creatinine. Nephro-urology monthly.

AK, A., & AK, A. (2015). Serum cystatin C and serum creatinine levels in type 2 diabetes mellitus. International Journal, 3(1), 174-178.

Published
2020-12-31
How to Cite
Al-Nasrawii, M. S., Sadoon Jasim, B., & Hussein Hassan, S. (2020). A COMPARATIVE ASSESSMENT OF SERUM CREATININE AND CYSTATIN C AS A SIGNIFICANCE OF NEPHROPATHY IN DIABETIC PATIENTS. Malaysian Journal of Public Health Medicine, 20(3), 189-194. https://doi.org/10.37268/mjphm/vol.20/no.3/art.527